Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF 994.5m

Cosmo Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Cosmo Pharmaceuticals has a total shareholder equity of €505.1M and total debt of €421.0K, which brings its debt-to-equity ratio to 0.08%. Its total assets and total liabilities are €646.8M and €141.7M respectively. Cosmo Pharmaceuticals's EBIT is €148.9M making its interest coverage ratio -92.1. It has cash and short-term investments of €143.0M.

Key information

0.083%

Debt to equity ratio

€421.00k

Debt

Interest coverage ratio-92.1x
Cash€142.96m
Equity€505.09m
Total liabilities€141.68m
Total assets€646.77m

Recent financial health updates

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Recent updates

author-image

Clascoterone Trials Completion And AI Expansion Will Open Future Markets

Strong cash position and no debt provide flexibility for strategic investments, boosting future profitability and earnings.

Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity

Jan 23
Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity
author-image

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Revenue: €265.7 million, representing a 186% year-over-year increase from €92.8 million in 2023. This includes €185 million in non-recurring revenues from Medtronic linked to the December 2023 expande

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Financial Position Analysis

Short Term Liabilities: COPN's short term assets (€202.3M) exceed its short term liabilities (€48.3M).

Long Term Liabilities: COPN's short term assets (€202.3M) exceed its long term liabilities (€93.4M).

Debt to Equity History and Analysis

Debt Level: COPN has more cash than its total debt.

Reducing Debt: COPN's debt to equity ratio has reduced from 40.4% to 0.08% over the past 5 years.

Debt Coverage: COPN's debt is well covered by operating cash flow (38577.4%).

Interest Coverage: COPN earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 18:42
End of Day Share Price 2025/07/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Silvia SchanzBank Vontobel AG
Laura HindleyBerenberg
Kerry HolfordBerenberg